Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 657179, 9 pages
http://dx.doi.org/10.1155/2015/657179
Research Article

Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines

1Department of General Clinical Medicine, Ohu University School of Dentistry, 31-1 Mitsumido, Tomiya-machi, Koriyama City, Fukushima 963-8611, Japan
2National Institute of Sensory Organs, National Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro, Tokyo 152-8902, Japan
3Department of Oral Function and Molecular Biology, Ohu University School of Dentistry, 31-1 Mitsumido, Tomiya-machi, Koriyama City, Fukushima 963-8611, Japan

Received 6 August 2014; Revised 7 November 2014; Accepted 7 November 2014

Academic Editor: Sandeep Singh

Copyright © 2015 Yuh Baba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Cripps, E. Winquist, M. C. Devries, D. Stys-Norman, and R. Gilbert, “Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer,” Current Oncology, vol. 17, no. 3, pp. 37–48, 2010. View at Google Scholar · View at Scopus
  2. F. R. Khuri, D. M. Shin, B. S. Glisson, S. M. Lippman, and W. K. Hong, “Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions,” Seminars in Oncology, vol. 27, supplement 8, no. 4, pp. 25–33, 2000. View at Google Scholar · View at Scopus
  3. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky, “Head and neck cancer,” The New England Journal of Medicine, vol. 345, no. 26, pp. 1890–1900, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Aggarwal, Y. Takada, S. Singh, J. N. Myers, and B. B. Aggarwal, “Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling,” International Journal of Cancer, vol. 111, no. 5, pp. 679–692, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Stell, “Time to recurrence of squamous cell carcinoma of the head and neck,” Head and Neck, vol. 13, no. 4, pp. 277–281, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Saranath, R. G. Panchal, R. Nair, A. R. Mehta, V. D. Sanghavi, and M. G. Deo, “Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer,” European Journal of Cancer Part B: Oral Oncology, vol. 28, no. 2, pp. 139–143, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Burtness, “The role of cetuximab in the treatment of squamous cell cancer of the head and neck,” Expert Opinion on Biological Therapy, vol. 5, no. 8, pp. 1085–1093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Baba, M. Fujii, Y. Tokumaru, and Y. Kato, “Present and future of EGFR inhibitors for head and neck squamous cell cancer,” Journal of Oncology, vol. 2012, Article ID 986725, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Murillo, J. W. Kosmeder II, J. M. Pezzuto, and R. G. Mehta, “Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice,” International Journal of Cancer, vol. 104, no. 1, pp. 7–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Gerhauser, W. Mar, N. Suh et al., “Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase,” Nature Medicine, vol. 1, no. 3, pp. 260–266, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. G. O. Udeani, C. Gerhäuser, C. F. Thomas et al., “Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid,” Cancer Research, vol. 57, no. 16, pp. 3424–3428, 1997. View at Google Scholar · View at Scopus
  14. H.-Y. Lee, S.-H. Oh, J. K. Woo et al., “Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis,” Journal of the National Cancer Institute, vol. 97, no. 22, pp. 1695–1699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-L. Yang, C. Ji, Z.-G. Bi et al., “Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells,” PLoS ONE, vol. 8, no. 1, Article ID e54736, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Mehta, H. Katta, F. Alimirah et al., “Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells,” PLoS ONE, vol. 8, no. 6, Article ID e65113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-A. Suh, J.-H. Kim, M. A. Sung et al., “A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer,” Cancer Letters, vol. 332, no. 1, pp. 102–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Baba, Y. Kato, I. Mochimatsu et al., “Inostamycin suppresses vascular endothelial growth factor-stimulated growth and migration of human umbilical vein endothelial cells,” Clinical and Experimental Metastasis, vol. 21, no. 5, pp. 419–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Erhardt, E. J. Schremser, and G. M. Cooper, “B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway,” Molecular and Cellular Biology, vol. 19, no. 8, pp. 5308–5315, 1999. View at Google Scholar · View at Scopus
  20. A. S. Nair, S. Shishodia, K. S. Ahn, A. B. Kunnumakkara, G. Sethi, and B. B. Aggarwal, “Deguelin, an Akt inhibitor, suppresses IκBα kinase activation leading to suppression of NF-κB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion,” The Journal of Immunology, vol. 177, no. 8, pp. 5612–5622, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-F. Yuen, O. Abramczykd, G. Montgomery et al., “Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells,” Bioscience Reports, vol. 32, no. 4, pp. 413–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Ramakrishnan, T. Kimlinger, J. Haug et al., “Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/ Akt and MEK/ERK pathway,” PLoS ONE, vol. 7, no. 11, Article ID e50005, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. H. Oh, J. K. Woo, Y. D. Yazici et al., “Structural basis for depletion of heat shock protein 90 client proteins by deguelin,” Journal of the National Cancer Institute, vol. 99, no. 12, pp. 949–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Ye, J. Hay, J. Laskin, J. Wu, and C. Ho, “Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab,” Journal of Cancer Research and Therapeutics, vol. 9, no. 4, pp. 607–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Jameson, A. D. Beckler, L. E. Taniguchi et al., “Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells,” Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2124–2134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Yan, Y. Wang, Q. Tan, R. A. Lubet, and M. You, “Efficacy of deguelin and silibinin on Benzo(a)pyrene-induced lung tumorigenesis in A/J Mice,” Neoplasia, vol. 7, no. 12, pp. 1053–1057, 2005. View at Publisher · View at Google Scholar · View at Scopus